[Form 4] Rhythm Pharmaceuticals, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Rhythm Pharmaceuticals (RYTM) – Form 4 insider activity

On 06/18/2025, director Christophe Jean converted 4,000 fully-vested restricted stock units (RSUs) into an equal number of common shares (transaction code M). The RSUs carried a $0.00 exercise price and represented a one-for-one right to common stock.

Following the conversion, Jean directly owns 7,000 Rhythm shares and no remaining RSUs, according to the filing. No sales were disclosed.

The filing documents a modest increase in board-level ownership without any market sale, offering a limited but positive alignment signal for shareholders.

Positive

• Director acquired 4,000 common shares via RSU vesting, increasing direct ownership to 7,000 shares.

Negative

• None.

Insights

Securities Analyst

TL;DR: Small insider share acquisition; negligible market impact.

The Form 4 shows a routine RSU conversion—4,000 units vested and settled into common stock at no cost, lifting the director’s direct stake to 7,000 shares. There is no cash consideration, share sale, or additional derivative exposure. Given the modest volume and absence of open-market buying or selling, I view the event as administrative rather than a valuation catalyst. Investor takeaway: neutral.

Corporate Governance Expert

TL;DR: Governance housekeeping; slightly better alignment, but immaterial.

The transaction finalizes a previously granted RSU award that fully vested on 06/18/2025. Settling RSUs into stock keeps compensation equity-based and eliminates outstanding derivatives, a straightforward practice in good governance. While any insider acquisition is directionally positive, the scale is too small to influence control or signaling dynamics. Overall impact: minimal.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

JEAN CHRISTOPHE

(Last) (First) (Middle)

222 BERKELEY STREET, 12TH FLOOR

(Street)

BOSTON MA 02116

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
RHYTHM PHARMACEUTICALS, INC. [ RYTM ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
06/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/18/2025		M		4,000	A	(1)	7,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	(1)	06/18/2025		M			4,000	(2)	(2)	Common Stock	4,000	$0.00	0	D

Explanation of Responses:

1. Each restricted stock unit represents a contingent right to receive one share of Issuer common stock.

2. The restricted stock units fully vested on June 18, 2025. The restricted stock units have no expiration date.

	/s/ Stephen Vander Stoep, attorney-in-fact for Christophe Jean	06/23/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Rhythm Pharmaceuticals (RYTM) shares did director Christophe Jean acquire on 06/18/2025?

He acquired 4,000 shares of common stock.

What transaction code was reported in the RYTM Form 4 filing?

The filing used transaction code M, indicating a derivative conversion.

What is Christophe Jean’s total direct share ownership after the transaction?

He now directly owns 7,000 shares.

Did the restricted stock units carry an exercise price?

No. The RSUs converted at an exercise price of $0.00.

When did the restricted stock units fully vest?

They fully vested on June 18, 2025.